Compounds > 5-dihydro-19-nortestosterone
Page last updated: 2024-11-06

5-dihydro-19-nortestosterone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-dihydro-19-nortestosterone (also known as 19-nortestosterone dihydrotestosterone or DHT) is a synthetic anabolic androgenic steroid (AAS) that is a derivative of 19-nortestosterone. It is structurally similar to dihydrotestosterone (DHT) and possesses strong androgenic activity. 5-dihydro-19-nortestosterone has been studied for its potential therapeutic effects, including its ability to promote muscle growth and increase bone density. However, it is also associated with significant adverse effects, including virilization in women and cardiovascular complications. The compound has been used in the past as an anabolic agent in veterinary medicine and human performance enhancement, but it is currently not approved for medical use in most countries. The research on this compound is mainly focused on understanding its mechanism of action, its potential therapeutic benefits and its side effects. The research is driven by the need to develop safer and more effective treatments for conditions such as muscle wasting and osteoporosis.'

5-dihydro-19-nortestosterone: RN given refers to (5 alpha,17 beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID94202
CHEMBL ID3137999
SCHEMBL ID6244377
MeSH IDM0113056

Synonyms (25)

Synonym
5.alpha.-estran-3-one, 17.beta.-hydroxy-
5-dihydronandrolone
(5s,8r,9r,10s,13s,14s,17s)-17-hydroxy-13-methyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-one
i0v6o3097q ,
5-dihydro-19-nortestosterone
1434-85-1
estran-3-one, 17-hydroxy-, (5alpha,17beta)-
unii-i0v6o3097q
CHEMBL3137999
SCHEMBL6244377
17beta-hydroxy-5alpha-estran-3-one
17.beta.-hydroxy-5.alpha.-estran-3-one
19-nor-5.alpha.-dihydrotestosterone
17.beta.-hydroxy-19-nor-5.alpha.-androstan-3-one
5.alpha.-dihydronandrolone
dihydronandrolone
5.alpha.-dihydro-19-nortestosterone
5.alpha.-estran-3-on-17.beta.-ol
17-hydroxyestran-3-one-, (5.alpha.,17.beta.)-
5alpha-dihydronandrolone
DTXSID60931866
q6j ,
Q27280217
'(5beta,9beta,10alpha,13alpha,14beta,17beta)-17-hydroxyestran-3-one'
(5beta,9beta,10alpha,13alpha,14beta,17beta)-17-hydroxyestran-3-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID19824Partition coefficient (logP)1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution.
AID162465Relative binding affinity (RBA) for Progesterone receptor in competitive radiometric assay1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution.
AID203786Relative binding affinity (RBA) for Sex steroid binding protein in competitive radiometric assay1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution.
AID226306Nonspecific binding (NSB) (R1881 = 1.00) calculated using an empirically derived relationship1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution.
AID227714Binding selectivity index (BSI) as ratio of RBA for androgen receptor to non-specific binding of R18811995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution.
AID39308Relative binding affinity (RBA) for Androgen receptor in competitive radiometric assay1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (80.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.51 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
nandrolone
Nandrolone: C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position.. nandrolone : A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17.		3.055017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid		human metabolite
dihydrotestosterone
Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.		2.663017beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
metribolone
Metribolone: A synthetic non-aromatizable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.. 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one : A synthetic non-aromatisable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.		1.981017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid		androgen
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Prostate
[description not available]		01.9810
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		01.9810
Blood Pressure, Low
[description not available]		01.9310
Hypotension
Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.		01.9310
Blood Pressure, High
[description not available]		01.9310
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		01.9310